FDA issues request for information to scale real‑time clinical‑trial review pilot
- FDA said April 28 it had started two real-time clinical-trial proofs of concept and opened a public RFI for a broader summer pilot. (fda.gov) - The named trials are AstraZeneca’s Phase 2 TRAVERSE study and Amgen’s Phase 1b STREAM-SCLC study; FDA said it already validated AstraZeneca signals. (fda.gov) - This pushes FDA from faster application review toward live trial oversight — with AI and data pipelines shaping earlier safety and go/no-go calls. (fda.gov)
Clinical trials are still mostly run like batch processing. Sites collect data, sponsors clean and analyze it, and regulators see the important(fda.gov)go calls can change the whole path of a drug. On April 28, the FDA said it wants to break that rhythm by moving toward real-time clinical-trial review, and it paired that announcement with a formal request for input on how to scale the idea. (fda.gov) ### What changed this week? The FDA did two concrete thing(fda.gov)leased a Request for Information for a broader pilot program planned for summer 2026. The agency framed both steps as part of a larger “real-time clinical trials” push. (fda.gov) ### Which trials are in it? The first named study is AstraZeneca’s TRAVERSE trial — a Phase 2, multi-site study in treatment-naive mantle cell lymphoma, with MD Anderson and the University of Pennsylvania involved. The second(fda.gov)n process. These are not hypothetical demos anymore; they are live sponsor programs. (fda.gov) ### What does “real time” mean here? Basically, the FDA wants to see key trial signals as the study runs instead of waiting for the usual spon(fda.gov)ich signals would be shared in real time. The FDA also said it has already received and validated signals from AstraZeneca’s trial through Paradigm Health, which is the technical proof that the data pipe can actually work. (fda.gov) ### Why is early phase the hard part? Early-phase trials are where uncertainty is highe(fda.gov)FDA’s RFI says the pilot is aimed at improving efficiency, speed, and decision quality in early-phase trials — especially safety monitoring, dose selection, and earlier go/no-go decisions on whether a study should keep moving. (public-inspection.federalregister.gov) ### Where does AI fit in? The new RFI is not just about faster data transfer. It is explicitly about “AI-enabled optimization” of early-phase trials. The FDA say(fda.gov) while the pilot itself would be guided by the NIST AI Risk Management Framework. So the pitch is not “let algorithms run the trial.” It is “use better tools so regulators and sponsors can react sooner.” (public-inspection.federalregister.gov) ### Is this the same as faster FDA approvals? Not exactly. The FDA already has a separate STAR pilot for split real-time application (public-inspection.federalregister.gov)am is about speeding review of supplemental applications after clinical work is largely done. This new effort moves upstream — into the trial itself, while evidence is still being generated. (fda.gov) ### What is the catch? The hard part is not the slogan. It is the plumbing and the rules. Real-time review only helps if the incoming data are trustworthy, the signal thresholds are agreed in advance, (public-inspection.federalregister.gov)s asking for public input on pilot design, metrics, and success criteria before the broader launch. Comments are due May 29, 2026. (fda.gov) ### Bottom line? This is the FDA trying to turn trial oversight from a delayed snapshot into a live feed. If it works, early drug development could get faster and safer a(fda.gov)ly chosen pilots. (fda.gov)
